Community Practice Connections™: 16th Annual New York Lung Cancers Symposium®

Release Date: January 7, 2022
Expiration Date: January 7, 2023

Activity Overview

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca, Bayer Healthcare Pharmaceuticals Inc., BeiGene USA, Inc., BeyondSpring Pharmaceuticals, Inc., Bristol Myers Squibb, Daiichi Sankyo, Inc, Exact Sciences Corporation, G1 Therapeutics, Inc., Genentech, Inc., Jazz Pharmaceuticals, Inc., Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc and Sanofi Genzyme, and Turning Point Therapeutics, Inc.
 

Target Audience

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Evaluate testing strategies to optimize tumor characterization and inform clinical decision-making for the management of patients with lung cancers
• Describe clinical trial evidence regarding the management of patients with non-metastatic lung cancers
• Apply evidence concerning single-agent and combination immunotherapeutic approaches to manage lung cancers
• Identify current and emerging therapeutic strategies over multiple lines of therapy for patients with oncogene-driven NSCLC subtypes
• Outline strategies for patients without actionable oncogenic drivers, including the role of chemotherapies and antiangiogenic strategies
• Summarize approaches to mitigate and manage treatment-related toxicities in the care of patients with lung cancers

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible companies.
 

Faculty

Balazs Halmos, MD, MS
Professor of Clinical Medicine
Director, Thoracic/Head and Neck Oncology
Director, Clinical Cancer Genomics
Albert Einstein College of Medicine/Montefiore Medical Center
Bronx, NY

Disclosures: Grant/Research Support: Mirati, AstraZeneca, Merck, Bristol Myers Squibb, Pfizer, AbbVie, GSK, Advaxis, Blueprint, Amgen; Consultant: AstraZeneca, Pfizer, Boehringer-Ingelheim, Genentech, Novartis, Bristol Myers Squibb, Amgen, TPT, Apollomics.

Mark G. Kris, MD
Attending Physician, Thoracic Oncology Service
William and Joy Ruane Chair in Thoracic Oncology
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Consultant: Astra Zeneca, Blueprint Medicines, BeiGene.

 

Roman Perez-Soler, MD
Chairman, Department of Oncology
Montefiore Medical Center
Professor of Medicine and Molecular Pharmacology
Deputy Director, Cancer Center
Albert Einstein College of Medicine
Bronx, NY

Disclosures: Consultant: Glaxo, Astra Zeneca, Clovis, Roche/Genentech, Boehringer, Lilly, Adgero; Shareholder: Stelexis.

Jamie E. Chaft, MD
Associate Attending Physician
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures:  Grant/Research Support: Bristol Myers Squibb, Genentech, AstraZeneca, Merck; Consultant: Genentech, AstraZeneca, Merck, Bristol Myers Squibb, Flame Biosciences, Guardant Health, Novartis, Janssen, Regeneron.

 

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.